Merck & Co gets in on the bispecific act
For $500m the big pharma group secures LaNova's anti-VEGF x PD-1 antibody.
Next for Trodelvy: small-cell lung cancer
Second-line NSCLC is a $1.8bn write-off, and Gilead plans phase 3 in SCLC.
SITC 2024 preview – duelling TIGIT duds
Failed trials of vibostolimab and domvanalimab will be unveiled at SITC late-breakers.
Triple meeting 2024 – casdatifan looks like Welireg
There’s little to distinguish the two HIF2α inhibitors in kidney cancer.
Triple meeting 2024 – Zai Lab impresses in small cell
ZL-1310 looks better than other DLL3-targeting agents, but two thirds of responses are so far unconfirmed.
Not so B-Fast for Roche
The focus for divarasib in second-line lung is now the head-to-head Krascendo-1 trial.
